Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elliquis

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

- PMLiVE

AstraZeneca bullish on diabetes franchise fortunes

Other big pharma firms face a difficult 2015, but AZ is confident it won't

- PMLiVE

NICE recommends BMS and Pfizer’s Eliquis for blood clots

Will be a treatment option for venous thromboembolism

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

National Institute for Health and Care Excellence NICE logo

Good NICE news for Pfizer, but Dendreon drug rejected

Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

- PMLiVE

Early win for Pfizer as Remicade biosimilar launches in West Europe

Hospira launchescopycat version of Janssen/MSD’s drug in major European markets

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

- PMLiVE

Pfizer UK appoints Erik Nordkamp as new managing director

He takes over from Jonathan Emms who moves to a global role within the firm

- PMLiVE

Pfizer’s bid for Hospira could lead to break-up

Questions posed whether $15bn bid will be profitable for the firm

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

- PMLiVE

Products over pipeline in Pfizer’s acquisition targets, hints CEO

Sale forecasts for 2015 are down by up to $5bn compared to last year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links